<DOC>
	<DOCNO>NCT00419003</DOCNO>
	<brief_summary>This study examine safety effectiveness two medication , ketamine riluzole , treat patient treatment resistant major depressive disorder . This study also examine effectiveness FDA approve drug call lamotrigine decrease potential side effect associate ketamine .</brief_summary>
	<brief_title>Research Study Major Depressive Disorder : Investigation Glutamate Medications</brief_title>
	<detailed_description>This research proposal investigate glutamate-modulating agent , riluzole , treatment-resistant patient exhibit acute , sustain response single dose intravenous ( IV ) racemic ketamine . Fifty ketamine-responders randomize riluzole placebo 4-week , randomize , double-blind , continuation-phase study .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>1 . Male female patient , 21 70 year age 2 . Subjects history least one previous episode depression prior current episode ( recurrent major depressive disorder ) chronic major depressive disorder ( least two year ' duration ) 3 . Subjects respond adequate trial one antidepressant current episode 1 . Female subject either pregnant nursing 2 . Serious , unstable illness 3 . Any previous use treatment ketamine , riluzole 4 . Past intolerance lamotrigine , include drug rash</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>